Abstracts Archive - Page 113 of 1683 - ATC Abstracts

2022 American Transplant Congress
Longitudinal Analysis of Donor-Derived Cell-Free DNA (dd-cfDNA) in En-Bloc Kidney Transplantation
S. K. Akkina¹, J. Klein², A. Khalil³, G. Shekhtman⁴, S. Patel⁴, N. Agrawal⁴, M. Fei⁴, N. Singh⁵, A. Desai¹
¹Loyola University Medical Center, Maywood, IL, ²University of Kansas Medical Center, Kansas City, KS, ³Dallas Nephrology Associates, Dallas, TX, ⁴CareDx, Brisbane, CA, ⁵Willis Knighton Health System, Shreveport, LA
*Purpose: The longitudinal dd-cfDNA patterns in en-bloc kidney transplant recipients have not been studied. It is unknown how the initial smaller mass of the two…
2022 American Transplant Congress
Incidence of Biliary Complications at the Beginning of the Academic Year in an Academic Transplant Program
M. E. Tobon Lascano, C. J. Simon, M. E. Akoad, J. Kim, M. Simpson, Y. Cheah
Transplant, Lahey Clinic, Burlington, MA
*Purpose: Surgery learning is based on a master-apprentice model, a learning curve is essential to measure the acquisition and improvement of surgical skills without compromising…
2022 American Transplant Congress
Deceased Donor Kidney Transplantation from Donors with Acute Kidney Injury: Realities and Costs
S. Iskhagi¹, R. Shahbazov¹, A. Ball¹, S. Loerzel¹, E. Shaban², B. Gallay², R. Hod Dvorai³, J. Leggat², M. Hanlon¹, R. Saidi¹
¹Department of Surgery, Division of Transplantation, SUNY Upstate Medical University, Syracuse, NY, ²Department of Medicine, Division of Nephrology, SUNY Upstate Medical University, Syracuse, NY, ³Department of Pathology and Laboratory Medicine, SUNY Upstate Medical University, Syracuse, NY
*Purpose: The use of kidneys from deceased donors with acute kidney injury (AKI) is one of the options to expand donor pool. Several studied have…
2022 American Transplant Congress
Renal Allograft Outcomes of Very High KDPI vs High KDPI Donor Kidneys
R. Rattanavich, R. Villicana
Transplant Nephrology, Transplant Institute Loma Linda University, Loma Linda, CA
*Purpose: Since KDPI > 85 donor kidneys have been commonly used among older recipients, renal allograft outcomes of very high KDPI (≥95) donors have been…
2022 American Transplant Congress
Preoperative Blood Pressure and Risk of Delayed Graft Function in Deceased Donor Kidney Transplantation
S. Wazir, M. Abbas, P. Ratanasreemehta, C. Zhang, C. M. Puttarajappa
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Evaluate association between preoperative blood pressure and delayed graft function (DGF) in deceased donor kidney transplantation (DDKT)*Methods: In this single center study of adult…
2022 American Transplant Congress
Post-Kidney Transplant Body Mass Index Trajectories Are Associated with Graft Loss and Mortality
Y. Liu¹, V. Bendersky¹, X. Chen¹, M. Harhay², D. Segev¹, M. McAdams-DeMarco¹
¹Johns Hopkins University, Baltimore, MD, ²Drexel University, Philadelphia, PA
*Purpose: Early post-kidney transplantation (KT) changes in physiology, medications, and health stressors likely impact body mass index (BMI). Hence, we sought to estimate trajectories of…
2022 American Transplant Congress
Single Center Retrospective Study Examining the Safety of the New Potassium- Binders for Post-Operative Hyperkalemia in Kidney Transplant Recipients
S. Kapoor¹, A. Campbell², Y. Azzi¹, L. E. Liriano-Ward³, T. Shertel⁴, W. Xiao⁵, D. U. Nnani⁶, S. Farghaly¹, S. Yun⁷, E. Akalin¹, M. Ajaimy¹
¹Einstein-Montefiore Transplant Center, Bronx, NY, ²Montefiore Medical Center, Bronx, NY, ³Transplant, Montefiore Medical Center, Bronx, NY, ⁴-, -, AL, ⁵Albert Einstein College of Medicine, Folsom, CA, ⁶Pharmacy, Montefiore Medical Center, Bronx, NY, ⁷Montefiore Medical Center, New York, NY
*Purpose: We aimed to evaluate the safety and efficacy of two potassium-binders (Patiromer and Sodium Zirconium Cyclosilicate (SZC) in early post-transplant hyperkalemia treatment of kidney…
2022 American Transplant Congress
Nebulized Mitochondria Localize to Transplanted Allografts and Improve Outcomes Following Lung Transplantation
D. Nord¹, Z. Tu², L. Langerude¹, A. McQuiston¹, J. Kwon³, S. Nadig⁴, T. Machuca⁵, C. Atkinson¹
¹Pulmonary Medicine, University of Florida, Gainesville, FL, ²University of Florida, Gaineville, FL, ³MUSC College of Medicine, Charleston, SC, ⁴Northwestern University, Charleston, SC, ⁵Department of Surgery, University of Florida, Gainesville, FL
*Purpose: Mitochondrial transplantation therapy is an innovative strategy for the treatment of mitochondrial dysfunction. The approach has shown efficacy in the treatment of cardiac ischemic…
2022 American Transplant Congress
Immunosuppressant Medications Use in Patients with Transplant Failure: A Canadian Multi-Centre Prospective Study
G. Knoll¹, M. Chassé², D. Fergusson³, A. A. House⁴, O. Johnston⁵, R. Mainra⁶, D. Baran⁷, D. Treleaven⁸, l. senecal⁹, L. Tibbles¹⁰, M. Hebert¹¹, M. Karpinski¹², T. Campbell¹³, T. Ramsay¹⁴, J. Kim¹⁵, I. Houde¹⁶, C. White¹⁷, J. Perl¹⁵, P. Karnabi¹⁸, J. Gill⁵
¹Nephrology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²University of Montreal, Montreal, QC, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴Nephrology, Western University, London, ON, Canada, ⁵Nephrology, University of British Columbia, Vancouver, BC, Canada, ⁶Nephrology, University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nephrology, McGill University, Montreal, QC, Canada, ⁸Nephrology, McMaster University, Hamilton, ON, Canada, ⁹Nephrology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada, ¹⁰Nephrology, University of Calgary, Calgary, AB, Canada, ¹¹Nephrology, University of Montreal, Montreal, QC, Canada, ¹²Nephrology, University of Manitoba, Winnipeg, MB, Canada, ¹³University of Alberta, Alberta, AB, Canada, ¹⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶Laval University, Que´bec, QC, Canada, ¹⁷Queen's University, Kingston, ON, Canada, ¹⁸Ottawa Health Research Institute, Ottawa, ON, Canada
*Purpose: This prospective study determined the association of immunosuppressant medication use with the outcomes of death, hospitalized infection, rejection of the failed allograft, and panel…
2022 American Transplant Congress
Outcomes After Conversion to Belatacept in Pediatric Kidney Transplantation
C. Duneton, A. Maisin, E. Cheyssac, H. Dahdouh, V. Baudouin, J. Hogan
Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France
*Purpose: Belatacept (CTLA-Ig) is a selective co-stimulation blocker that is associated with reduced dnDSA, improved renal function, and prolonged allograft survival in adult transplant recipients…